BioNTech (BNTX) CEO Ugur Sahin Sells 73,000 Shares

What Happened

• Ugur Sahin, CEO of BioNTech SE, reported sales of a total 73,000 ordinary shares in two transactions. On 2026-09-08 he sold 37,000 shares at $99.20 each for $3,670,518, and on 2026-09-09 he sold 36,000 shares at $97.78 each for $3,520,145. The combined proceeds are approximately $7.19 million. These were reported as disposals (sales), which are often routine insider selling rather than a purchase signal.

Key Details

• Transaction dates and prices:
  • 2026-09-08: 37,000 shares sold at $99.20 — $3,670,518
  • 2026-09-09: 36,000 shares sold at $97.78 — $3,520,145
• Total shares sold: 73,000; total proceeds: ~$7.19M.
• Shares owned after transaction: Not specified in the provided excerpt of the Form 4.
• Footnote: The shares are held by Medine GmbH; Sahin is the sole shareholder of Medine GmbH. 106,721 of the ordinary shares reported are held in trust for an individual, with Medine GmbH exercising voting but not dispositive power over those shares. Sahin may be deemed to beneficially own the shares held by Medine GmbH.
• Plan/authorization: Sales were effected under a Rule 10b5-1 trading plan established by Sahin on June 3, 2026.
• Filing timeliness: Form 4 was filed on 2026-09-09 for transactions on 2026-09-08 and 2026-09-09 — appears to be filed within the usual 2-business-day window.

Context

• This filing reports sales, which are common for executives and may be scheduled through 10b5-1 plans; it does not necessarily indicate a change in the executive’s view of the company. The 10b5-1 plan note indicates these trades were pre-planned rather than ad hoc.